Table 1.
Demographic and clinical data of patients with RA and healthy control subjects.
| Controls | RA | |||
|---|---|---|---|---|
| Non-CP | CP | Non-CP | CP | |
| Subjects | 27 (57.4%) | 20 (42.6%) | 21 (50%) | 21 (50%) |
| Females % | 36.5 | 48 | 53.48 | 34 |
| Age, years | 42.8 (±14.0) | 46.5 (±12.3) | 50 (±11.1) | 53 (±10.40) |
| Current Smokers | 1 (3.7%) | 2 (7.6%) | 1 (4.6%) | 1 (4.6%) |
| RA duration, years | n/a | n/a | 16.2 (±8.2) | 12.5 (±9.7) |
| Disease active parameters | ||||
| Tender joints | n/a | n/a | 3.2 (±4.0) | 3.3 (±4.6) |
| Swollen joints | n/a | n/a | 2.5 (±0.5) | 2.4 (±0.9) |
| DAS28 | n/a | n/a | 3.5 (±1.2) | 3.7 (±1.5) |
| Autoantibody status | ||||
| ACPA positive, % | n/a | n/a | 7 (33%) | 85.7* |
| Medications | ||||
| Methotrexate | n/a | n/a | 11 (52.4%) | 14 (66.7%) |
| Prednisone | n/a | n/a | 9 (42.9%) | 14 (66.7%) |
| Biological agent | n/a | n/a | 5 (23.8%) | 4 (19.0%) |
| Periodontal parameters | ||||
| PD (mm) | 1.9 (1.6–2.2) | 3.0 (3–3.7)* | 2.9 (2–3)# | 3.8 (3.4–4.5)*,# |
| CAL (mm) | 2.2 (2–3) | 3.0 (2.6–3.5) | 3.0 (2.9–3.4) | 4.0 (3.7–5.3)*,# |
| BOP (% sites) | 6 (1.2–16) | 6.7 (2.7–13) | 5 (3.8–7.7) | 7 (5–14) |
| Missing teeth | 2 (0–6) | 4 (1–7) | 6 (2.5–11)# | 6 (3–10) |
| Plaque Index | 0.5 (0.1–1) | 0.5 (0.3–0.8) | 0.5 (0.2–0.7) | 0.58 (0.23–1.1) |
| Tooth brushing (times/day) | 2.85 (±0.93) | 2.62 (±0.85) | 2.82 (±0.5) | 2.69 (±0.6) |
Values were expressed in mean ± SD or median (25% percentile-75% percentile).
CP: Chronic Periodontitis, BOP: bleeding upon probing, PD probing depth, CAL clinical attachment level, DAS28: Disease Activity Score, ACPA anti-citrullinated protein antibody.
*Statistically different comparing Non-CP × CP within the same group.
#Statistically different comparing RA × Healthy Control group with the same periodontal status.
One Way ANOVA or Kruskal-Wallis test, p < 0.05.